HIV-associated lymphoproliferative disorders: Single-center experience

Survival rates of human immunodeficiency virus-positive subjects improved in recent years, especially due to innovations in current lymphoma treatments and the addition of combination antiretroviral therapy (cART). This study presents demographic and clinical characteristics, prognosis, and survival data of acquired immune deficiency syndrome (AIDS)-related lymphoma patients as a single-center experience. This retrospective study included 16 patients with AIDS-related lymphoma treated at our center between August 2010 and March 2022. Demographic data, clinical information, treatment details, and survival analysis of the patients were retrospectively reviewed from the relevant clinical archives. Fifteen out of 16 patients were males with a median age of 46.5 years (range, 24-71 years). The diagnoses were as follows: diffuse large B-cell lymphoma in 6, Burkitt lymphoma in 4, Hodgkin lymphoma in 3, plasmablastic lymphoma in 1, primary central nervous system lymphoma in 1, and chronic lymphocytic leukemia in 1 out of 16 patients. Fifteen patients presented with an advanced stage at diagnosis. Diagnosis of AIDS preceded the onset of lymphoma in 11 patients. The time from human immunodeficiency virus infection to diagnosis of lymphoma was 23.8 months (range, 1-185 months). All patients received cART during lymphoma treatment. The treatment response was evaluated in all patients who completed the initial treatment. Eleven patients (68.8%) are still alive with a complete response. Antitumour treatments administered in conjunction with cART have a favorable impact on survival and response rates in this aggressive group of patients.